+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

SHIP2: an emerging target for the treatment of type 2 diabetes mellitus



SHIP2: an emerging target for the treatment of type 2 diabetes mellitus



Current Drug Targets. Immune Endocrine and Metabolic Disorders 3(4): 291-298



With the rapid increase in the number of patients developing type 2 diabetes mellitus and the lack of optimal therapies, much focus has been placed on the insulin-signaling pathway in the discovery of novel drug targets. Phosphatidyl Inositol 3-Kinase (PI3K) is central to mediating insulin-s metabolic effects. PI3K catalyzes the generation of phosphatidyl inositol (3,4,5) triphosphate (PIP(3)). Inhibition of PI3K activity results in a blockade of insulin signaling including glucose uptake and glyocogen synthesis. Thus, PIP(3) is a critical mediator of insulin action. A family of phosphatidyl inositol phosphatases have been identified that counter-regulate PI3K activity by hydrolyzing PIP(3) to phosphatidyl inositol bisphosphate at either the 3' or 5' position of the inositol ring. Mice lacking one of these enzymes, Src-Homology Inositol Phosphatase-2 (SHIP2), demonstrate increased insulin sensitivity, suggesting that pharmacological inhibition of SHIP2 could alleviate insulin resistance. Recent studies demonstrate elevated SHIP2 expression is associated with insulin resistance in human patients. Comparing the studies on SHIP2 and other phosphatases suggests how inhibition of SHIP2 leads to increased insulin sensitivity without deleterious effects. This review focuses on the emergence of SHIP2 as a target in the insulin-signaling pathway for the treatment of type 2 diabetes.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035689205

Download citation: RISBibTeXText

PMID: 14683460


Related references

Ship2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus. Current Drug Targets - Immune, Endocrine & Metabolic Disorders 3(4): 291-298, 2003

Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus. Medicinal Research Reviews 36(4): 672-704, 2016

Glucose variability: An emerging target for the treatment of diabetes mellitus. Diabetes Research and Clinical Practice 102(2): 86-95, 2013

From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Current Medical Research and Opinion 25(3): 671-681, 2009

Single nucleotide polymorphisms on SHIP2 is associated with Type 2 diabetes mellitus in Chinese Han population. European Review for Medical and Pharmacological Sciences 19(1): 129-137, 2015

Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. Medicinal Research Reviews 38(2): 381-425, 2018

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. Journal of Clinical Pharmacology 52(4): 457-463, 2012

Management of type 2 diabetes mellitus in older patients: current and emerging treatment options. Diabetes Therapy 4(2): 239-256, 2013

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabetic Medicine 26(12): 1185-1192, 2009

Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists. Clinical Therapeutics 37(3): 483-493, 2015

GPR43: an emerging target for the potential treatment of type 2 diabetes, obesity and insulin resistance. Current Opinion in Investigational Drugs 11(4): 385-393, 2010

"SHIP2 and insulin signaling: what is its role in the pathogenesis and treatment of type 2 diabetes?". Bulletin et Memoires de l'Academie Royale de Medecine de Belgique 158(7-9): 335-9; Discussion 340, 2003

A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans. Journal of Pharmacological and Toxicological Methods 84: 20-30, 2016

ROS acts as a double-edged sword in the pathogenesis of type 2 diabetes mellitus: is Nrf2 a potential target for the treatment?. Mini Reviews in Medicinal Chemistry 11(12): 1082-1092, 2011

Ros Acts as a Double-Edged Sword in the Pathogenesis of Type 2 Diabetes Mellitus: Is Nrf2 a Potential Target for the Treatment?. Mini-Reviews in Medicinal Chemistry 11(12): 1082-1092, 2011